Skip to Content

935 Results Found

  • Article
  • Open Access
24 Citations
7,747 Views
19 Pages

Long-Term Systemic Expression of a Novel PD-1 Blocking Nanobody from an AAV Vector Provides Antitumor Activity without Toxicity

  • Noelia Silva-Pilipich,
  • Eva Martisova,
  • María Cristina Ballesteros-Briones,
  • Sandra Hervas-Stubbs and ,
  • Noelia Casares,
  • Gualberto González-Sapienza,
  • Cristian Smerdou and
  • Lucia Vanrell
  • + 3 authors+ 0 author

Immune checkpoint blockade using monoclonal antibodies (mAbs) able to block programmed death-1 (PD-1)/PD-L1 axis represents a promising treatment for cancer. However, it requires repetitive systemic administration of high mAbs doses, often leading to...

(This article belongs to the Section Immunology and Immunotherapy)
  • Article
  • Open Access
29 Citations
3,425 Views
11 Pages

The adsorption and sensing behavior of three typical industrial toxic gases NO, NO2 and SO2 by the Pd modified C3N monolayer were studied in this work on the basic first principles theory. Meanwhile, the feasibility of using the Pd doped C3N monolaye...

(This article belongs to the Special Issue State-of-the-Art Nanomaterials and Nanotechnology in China)
  • Article
  • Open Access
14 Citations
4,062 Views
19 Pages

Preclinical Toxicity and Safety of MM-129—First-in-Class BTK/PD-L1 Inhibitor as a Potential Candidate against Colon Cancer

  • Justyna Magdalena Hermanowicz,
  • Bartlomiej Kalaska,
  • Krystyna Pawlak,
  • Beata Sieklucka and ,
  • Joanna Miklosz,
  • Mariusz Mojzych and
  • Dariusz Pawlak
  • + 2 authors+ 0 author

MM-129 is a novel inhibitor targeting BTK/PI3K/AKT/mTOR and PD-L1, as it possesses antitumor activity against colon cancer. To evaluate the safety profile of MM-129, we conducted a toxicity study using the zebrafish and rodent model. MM-129 was also...

  • Article
  • Open Access
  • Best Paper Award
52 Citations
7,551 Views
14 Pages

Effect of Noble Metals (Ag, Pd, Pt) Loading over the Efficiency of TiO2 during Photocatalytic Ozonation on the Toxicity of Parabens

  • João F. Gomes,
  • Ana Lopes,
  • Katarzyna Bednarczyk,
  • Marta Gmurek and ,
  • Marek Stelmachowski,
  • Adriana Zaleska-Medynska,
  • M. Emília Quinta-Ferreira,
  • Raquel Costa,
  • Rosa M. Quinta-Ferreira and
  • Rui C. Martins
  • + 5 authors+ 0 author

The conventional wastewater treatments are inadequate for emerging contaminants detoxification. Photocatalytic ozonation with suitable catalyst can be considered as a suitable solution on the removal of these compounds. The aim of this study was to v...

  • Systematic Review
  • Open Access
1 Citations
1,983 Views
16 Pages

PD-L1-Guided Chemo-Immunotherapy in Advanced Triple-Negative Breast Cancer: A Meta-Analysis of Survival Benefits and Toxicity Profiles

  • Lingshan Nan,
  • Xi Zuo,
  • Xiaohui Yin,
  • Haiming Li and ,
  • Yue Wang,
  • Xiaomin Wang,
  • Dong Chen and
  • Ganlin Zhang
  • + 3 authors+ 0 author

23 April 2026

Importance: Triple-negative breast cancer (TNBC) is characterized by high tumor mutation burden and frequent programmed cell death ligand 1 (PD-L1) expression, making immune checkpoint inhibitors (ICIs) a promising therapeutic approach. However, rand...

(This article belongs to the Section Cancer Therapy)
  • Article
  • Open Access
50 Citations
20,659 Views
30 Pages

We hypothesize that different routes of administration may lead to altered pharmacokinetics/pharmacodynamics (PK/PD) behavior of antibody-drug conjugates (ADCs) and may help to improve their therapeutic index. To evaluate this hypothesis, here we per...

(This article belongs to the Special Issue Antibody Drug Conjugates: Unlocking the Future of Immunotherapies)
  • Article
  • Open Access
58 Citations
4,386 Views
9 Pages

Safety of Immune Checkpoint Inhibitors in Elderly Patients: An Observational Study

  • Agnese Paderi,
  • Sara Fancelli,
  • Enrico Caliman,
  • Serena Pillozzi and ,
  • Elisabetta Gambale,
  • Marinella Micol Mela,
  • Laura Doni,
  • Francesca Mazzoni and
  • Lorenzo Antonuzzo
  • + 4 authors+ 0 author

25 August 2021

Background: Immunotherapy has completely changed the treatment of solid tumors. Although immune checkpoint inhibitors (ICIs) seem to be an appealing alternative to chemotherapy, especially in elderly patients, due to a more tolerable toxicity profile...

  • Article
  • Open Access
9 Citations
4,019 Views
11 Pages

Immune-Checkpoint-Inhibitor-Related Lung Toxicity: A Multicentre Real-Life Retrospective Portrait from Six Italian Centres

  • Paolo Cameli,
  • Paola Faverio,
  • Katia Ferrari,
  • Viola Bonti and ,
  • Stefania Marsili,
  • Maria Antonietta Mazzei,
  • Francesca Mazzoni,
  • Maurizio Bartolucci,
  • Vieri Scotti and
  • Fabrizio Luppi
  • + 15 authors+ 10 authors

29 July 2022

Background: Immune checkpoint inhibitors (ICIs) have revolutionized the therapeutic horizons of various cancers. However, immune-related adverse events have been reported, including interstitial lung diseases. Our aim was to describe the clinical and...

(This article belongs to the Special Issue Thoracic Malignancies: From Prevention and Diagnosis to Late Stages)
  • Systematic Review
  • Open Access
105 Citations
9,368 Views
24 Pages

Cardiac Toxicity Associated with Immune Checkpoint Inhibitors: A Systematic Review

  • Walid Shalata,
  • Amjad Abu-salman,
  • Rachel Steckbeck,
  • Binil Mathew Jacob and ,
  • Ismaell Massalha and
  • Alexander Yakobson
  • + 1 author+ 0 author

18 October 2021

Immune checkpoint inhibitors are immune stimulatory drugs used to treat many types of cancer. These drugs are antibodies against inhibitory proteins, such as CTLA-4 and PD-1/PD-L1, that are expressed on immune cells. When bound, they allow for increa...

(This article belongs to the Special Issue Cancer Immunotherapy and Immune-Related Adverse Events)
  • Article
  • Open Access
8 Citations
4,411 Views
21 Pages

Metabolic Impact of Anticancer Drugs Pd2Spermine and Cisplatin on the Brain of Healthy Mice

  • Tatiana J. Carneiro,
  • Martin Vojtek,
  • Salomé Gonçalves-Monteiro,
  • João R. Neves and ,
  • Ana L. M. Batista de Carvalho,
  • Maria Paula M. Marques,
  • Carmen Diniz and
  • Ana M. Gil
  • + 3 authors+ 0 author

The new palladium agent Pd2Spermine (Spm) has been reported to exhibit promising cytotoxic properties, while potentially circumventing the known disadvantages associated to cisplatin therapeutics, namely acquired resistance and high toxicity. This wo...

(This article belongs to the Special Issue Beyond the Platinum in Metal-Based Cancer Therapy)
  • Article
  • Open Access
9 Citations
3,338 Views
27 Pages

28 March 2023

In glucose metabolism, the pentose phosphate pathway (PPP) is the major metabolic pathway that plays a crucial role in cancer growth and metastasis. Although it has been pointed out that blockade of the PPP is a promising approach against cancer, in...

(This article belongs to the Special Issue Recent Advances in Carbohydrates, Glycosides, and Nucleosides for Biological and Computational Research)
  • Case Report
  • Open Access
1 Citations
1,476 Views
12 Pages

Does Glucose-6-Phosphate Dehydrogenase Deficiency Correlate with Increased Sensitivity to Cisplatin? A Case Report and a Narrative Literature Review

  • Nerina Denaro,
  • Valeria Smiroldo,
  • Claudia Bareggi,
  • Cinzia Solinas and ,
  • Michele Ghidini,
  • Massimo Castellani,
  • Marco Carlo Merlano,
  • Serafina Martella,
  • Riccardo Giossi and
  • Ornella Garrone
  • + 6 authors+ 1 author

Glucose-6-phosphate dehydrogenase (G6PD) deficiency impairs NADPH generation through the pentose phosphate pathway, resulting in reduced glutathione regeneration and increased vulnerability to oxidative stress. While its clinical significance is well...

(This article belongs to the Section Molecular Oncology)
  • Article
  • Open Access
75 Citations
7,324 Views
22 Pages

Disorder of Coagulation-Fibrinolysis System: An Emerging Toxicity of Anti-PD-1/PD-L1 Monoclonal Antibodies

  • Ryo Sato,
  • Kosuke Imamura,
  • Shinya Sakata,
  • Tokunori Ikeda and ,
  • Yuko Horio,
  • Shinji Iyama,
  • Kimitaka Akaike,
  • Shohei Hamada,
  • Takayuki Jodai and
  • Takuro Sakagami
  • + 11 authors+ 6 authors

A disruption of immune checkpoints leads to imbalances in immune homeostasis, resulting in immune-related adverse events. Recent case studies have suggested the association between immune checkpoint inhibitors (ICIs) and the disorders of the coagulat...

(This article belongs to the Special Issue Human Cancer Immunotherapy with Antibodies to the PD-1 and PD-L1 Pathway)
  • Article
  • Open Access
32 Citations
5,600 Views
16 Pages

Is there an Exposure–Response Relationship for Nivolumab in Real-World NSCLC Patients?

  • Audrey Bellesoeur,
  • Edouard Ollier,
  • Marie Allard,
  • Laure Hirsch and ,
  • Pascaline Boudou-Rouquette,
  • Jennifer Arrondeau,
  • Audrey Thomas-Schoemann,
  • Manuela Tiako,
  • Nihel Khoudour and
  • Benoit Blanchet
  • + 14 authors+ 9 authors

13 November 2019

Pharmacokinetic/pharmacodynamic data from real-world cohort are sparse in non small–cell lung cancer (NSCLC) patients treated with nivolumab. The aim of this prospective observational study was to explore the exposure-response relationship for...

(This article belongs to the Special Issue Cancer Biomarkers)
  • Article
  • Open Access
12 Citations
4,312 Views
18 Pages

26 November 2019

Sesterterpene MHO7 derived from mangrove fungus is a novel estrogen receptor degrader for the treatment of breast cancer. To explore its safety and pharmacokinetics in vivo, Log P/D values, stability in simulated gastric/intestinal (SGF/SIF), toxicit...

(This article belongs to the Special Issue Pharmacokinetic Research of Marine Drugs)
  • Article
  • Open Access
5 Citations
2,209 Views
25 Pages

Green Synthesis of Au-Pd Bimetallic Nanoparticles Using Aspalathin and Their Toxicity Study

  • Naledi D. Seatle,
  • Akeem O. Akinfenwa,
  • Keenau M. Pearce,
  • Idowu J. Sagbo and ,
  • Mongi Benjeddou and
  • Ahmed A. Hussein
  • + 1 author+ 0 author

Bimetallic nanoparticles have garnered significant attention in scientific literature due to their diverse applications and unique properties. Concurrently, green synthesis methodologies have emerged as environmentally friendly alternatives, reducing...

(This article belongs to the Section Medicinal Chemistry)
  • Case Report
  • Open Access
6 Citations
4,278 Views
11 Pages

Immune-Checkpoint Induced Skin Toxicity Masked as Squamous Cell Carcinoma: Case Report on Mimickers of Dermatological Toxicity with PD-1 Inhibition

  • Sze Wah Samuel Chan,
  • Rahul Shukla,
  • Jennifer Ramsay,
  • Elaine McWhirter and ,
  • Paul Barnfield and
  • Rosalyn A. Juergens
  • + 1 author+ 0 author

27 April 2023

Background: Immune checkpoint inhibitors (ICI) are increasingly the mainstay of oncology treatment. Immune-related adverse events (irAEs) from ICI therapy differ from cytotoxic adverse events. Cutaneous irAEs are one of the most common irAEs and requ...

(This article belongs to the Special Issue Immune Checkpoint Inhibitors in Cancer Therapy: State of the Art and Future Perspectives)
  • Review
  • Open Access
26 Citations
9,230 Views
13 Pages

PD-1 Inhibitors-Related Neurological Toxicities in Patients with Non-Small-Cell Lung Cancer: A Literature Review

  • Aurora Mirabile,
  • Elena Brioschi,
  • Monika Ducceschi,
  • Sheila Piva and ,
  • Chiara Lazzari,
  • Alessandra Bulotta,
  • Maria Grazia Viganò,
  • Giovanna Petrella,
  • Luca Gianni and
  • Vanesa Gregorc
  • + 5 authors+ 0 author

1 March 2019

The advent of immune checkpoint inhibitors gave rise to a new era in oncology and general medicine. The increasing use of programmed death-1 (PD-1) inhibitors in non-small cell lung cancer and in other malignancies means clinicians have to face up to...

  • Case Report
  • Open Access
3 Citations
2,846 Views
12 Pages

Immunohistochemical Evaluation of Renal Biopsy with Anti-PD1 and p53 to Solve the Dilemma between Platinum- and Pembrolizumab-Induced AKI: Case Report and Review

  • Nicoletta Mancianti,
  • Sergio Antonio Tripodi,
  • Alessandra Pascucci,
  • Marta Calatroni and ,
  • Edoardo La Porta,
  • Andrea Guarnieri and
  • Guido Garosi
  • + 2 authors+ 0 author

22 March 2024

Introduction: The combination therapy of platinum and pembrolizumab looks like a promising treatment in advanced non-small-cell lung cancer. However, both platinum-based chemotherapy and pembrolizumab can lead to AKI. AKI can occur due to acute tubul...

(This article belongs to the Special Issue Acute Kidney Injury Due to Numerous Etiologies)
  • Systematic Review
  • Open Access
6 Citations
2,640 Views
17 Pages

Renal Toxicities in Cancer Patients Receiving Immune-Checkpoint Inhibitors: A Meta-Analysis

  • Matteo Righini,
  • Veronica Mollica,
  • Alessandro Rizzo,
  • Gaetano La Manna and
  • Francesco Massari

27 July 2022

Aim: We performed a meta-analysis of the available clinical trials of immune-checkpoint inhibitors to assess risk differences and relative risks of renal toxicity. Methods: 17 randomized phase III studies were selected, including 10,252 patients. Res...

(This article belongs to the Special Issue Advances in Kidney Disease and Transplantation)
  • Review
  • Open Access
31 Citations
5,427 Views
23 Pages

Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: An Overview

  • Diederick J. van Doorn,
  • Robert Bart Takkenberg and
  • Heinz-Josef Klümpen

22 December 2020

Patients with hepatocellular carcinoma (HCC) face a common type of cancer, which is amongst the most deadly types of cancer worldwide. The therapeutic options range from curative resection or ablation to loco regional therapies in palliative setting...

(This article belongs to the Special Issue New Therapies for Hepatocellular Carcinoma)
  • Review
  • Open Access
10 Citations
5,631 Views
24 Pages

Real Impact of Novel Immunotherapy Drugs in Cancer. The Experience of 10 Last Years

  • Andreas Koulouris,
  • Christos Tsagkaris and
  • Michail Nikolaou

15 February 2021

Intense research on immunotherapy has been conducted during recent years. As advances in the field have started changing the landscape of cancer therapy, it is necessary to assess the impact of immunotherapeutic modalities in the treatment of various...

  • Review
  • Open Access
8 Citations
3,881 Views
15 Pages

Tolerated Re-Challenge of Immunotherapy in a Patient with ICI Associated Myocarditis: A Case Report and Literature Review

  • Walid Shalata,
  • Zoé Gabrielle Attal,
  • Rajeh Shhadi,
  • Amjad Abu Salman and ,
  • Ashraf Abu Jama,
  • Sondos Shalata,
  • Kais Halumi and
  • Alexander Yakobson
  • + 3 authors+ 0 author

3 November 2023

Many different types of cancer can be treated with immunotherapy drugs called immune checkpoint inhibitors (ICIs). These drugs have altered the landscape of cancer treatment options since they function by triggering a stronger immune response to mali...

(This article belongs to the Special Issue Innovations in the Field of Cardio-Oncology)
  • Article
  • Open Access
8 Citations
3,883 Views
16 Pages

Endocrine Immune-Related Adverse Events Are Independent Predictors of Survival in Patients with Lung Cancer

  • Emmanouil Panagiotou,
  • Sofia Ntouraki,
  • Ioannis A. Vathiotis,
  • Maria Effrosyni Livanou and ,
  • Athanasios Trimis,
  • Georgios Evangelou,
  • Andriani Charpidou,
  • Konstantinos Syrigos and
  • Melpomeni Peppa
  • + 4 authors+ 0 author

1 May 2024

Lung cancer (LC) is a serious health problem worldwide. Survival outcomes have improved over time due to the widespread use of novel therapeutic agents, including immune checkpoint inhibitors (ICIs). Endocrine immune-related adverse events (e-irAEs)...

(This article belongs to the Section Cancer Immunology and Immunotherapy)
  • Review
  • Open Access
9 Citations
4,923 Views
15 Pages

Immune checkpoint inhibitors herald a new era in oncological therapy-resistant cancer, thus bringing hope for better outcomes and quality of life for patients. However, as with other medications, they are not without serious side effects over time. D...

(This article belongs to the Collection Feature Papers in Cell Biology and Pathology)
  • Article
  • Open Access
13 Citations
3,831 Views
11 Pages

Immune Checkpoint Blockade for Metastatic Uveal Melanoma: Re-Induction following Resistance or Toxicity

  • Elias A. T. Koch,
  • Anne Petzold,
  • Anja Wessely,
  • Edgar Dippel and ,
  • Anja Gesierich,
  • Ralf Gutzmer,
  • Jessica C. Hassel,
  • Sebastian Haferkamp,
  • Katharina C. Kähler and
  • Markus V. Heppt
  • + 26 authors+ 21 authors

20 January 2022

Re-induction with immune checkpoint blockade (ICB) needs to be considered in many patients with uveal melanoma (UM) due to limited systemic treatment options. Here, we provide hitherto the first analysis of ICB re-induction in UM. A total of 177 pati...

(This article belongs to the Special Issue Uveal Melanoma: From Diagnosis to Therapy)
  • Article
  • Open Access
11 Citations
4,209 Views
12 Pages

10 March 2022

Approved adjuvant treatment options for stage III melanoma are the immune checkpoint inhibitors (ICI) pembrolizumab and nivolumab, and in presence of a BRAF V600E/K mutation additionally dabrafenib in combination with trametinib (BRAFi/MEKi). This st...

(This article belongs to the Section Cancer Biology)
  • Article
  • Open Access
1,210 Views
10 Pages

4 October 2025

Background/Objectives: Immune checkpoint inhibitors (ICIs) have revolutionized outcomes for patients with melanoma. As such, it is important to understand factors that may influence response as well as toxicity to these therapies. Impaired glucose co...

(This article belongs to the Section Cancer Immunology and Immunotherapy)
  • Article
  • Open Access
29 Citations
4,727 Views
16 Pages

Exploring the Release of Toxic Oligomers from α-Synuclein Fibrils with Antibodies and STED Microscopy

  • Alessandra Bigi,
  • Emilio Ermini,
  • Serene W. Chen,
  • Roberta Cascella and
  • Cristina Cecchi

11 May 2021

α-Synuclein (αS) is an intrinsically disordered and highly dynamic protein involved in dopamine release at presynaptic terminals. The abnormal aggregation of αS as mature fibrils into intraneuronal inclusion bodies is directly linked to Parkinson’s d...

(This article belongs to the Section Genomics and Proteomics)
  • Review
  • Open Access
26 Citations
7,733 Views
24 Pages

19 February 2017

Pharmacoproteomics is the study of disease-modifying and toxicity parameters associated with therapeutic drug administration, using analysis of quantitative and temporal changes to specific, predetermined, and select proteins, or to the proteome as a...

(This article belongs to the Special Issue Pharmacogenetics and Personalized Medicine 2016)
  • Review
  • Open Access
90 Citations
6,387 Views
22 Pages

Pathophysiological Features of Nigral Dopaminergic Neurons in Animal Models of Parkinson’s Disease

  • Ezia Guatteo,
  • Nicola Berretta,
  • Vincenzo Monda,
  • Ada Ledonne and
  • Nicola Biagio Mercuri

The degeneration of nigral dopaminergic neurons is considered the hallmark of Parkinson’s disease (PD), and it is triggered by different factors, including mitochondrial dysfunction, Lewy body accumulation, neuroinflammation, excitotoxicity and...

(This article belongs to the Section Molecular Neurobiology)
  • Article
  • Open Access
2 Citations
2,082 Views
19 Pages

From Intensification to Optimization: Balancing Efficacy, Safety, and Costs in High-Risk Localized Soft Tissue Sarcomas

  • Bruno Fuchs,
  • Georg Schelling,
  • Christoph Glanzmann,
  • Gabriela Studer and
  • on behalf of the Swiss Sarcoma Network

21 May 2025

Background/Objectives: The SU2C-SARC032 randomized controlled trial (RCT) tested pembrolizumab combined with preoperative normofractionated radiotherapy as an intensified treatment for high-risk stage III resectable soft tissue sarcoma (STS), demonst...

(This article belongs to the Section Cancer Therapy)
  • Article
  • Open Access
23 Citations
2,620 Views
9 Pages

1 October 2020

Background: Immune checkpoint inhibitors (icis), including inhibitors of PD-1, PD-L1, and ctla-4, are relatively novel therapies for lung cancer, although their use might be limited by gastrointestinal toxicity. The aim of the present study was to de...

  • Article
  • Open Access
8 Citations
2,598 Views
11 Pages

Pd3Co1 Alloy Nanocluster on the MWCNT Catalyst for Efficient Formic Acid Electro-Oxidation

  • Pingping Yang,
  • Li Zhang,
  • Xuejiao Wei,
  • Shiming Dong and
  • Yuejun Ouyang

25 November 2022

In this study, the Pd3Co1 alloy nanocluster from a multiwalled carbon nanotube (MWCTN) catalyst was fabricated in deep eutectic solvents (DESs) (referred to Pd3Co1/CNTs). The catalyst shows a better mass activity towards the formic acid oxidation rea...

(This article belongs to the Section Biology and Medicines)
  • Article
  • Open Access
6 Citations
6,602 Views
12 Pages

2 November 2015

We previously prepared and evaluated simple Eudragit S100 microparticles loaded with prednisolone (ES-MP) and Eudragit S100-coated chitosan-succinyl-prednisolone conjugate microparticles (Ch-MP/ES) in vitro. In this work, the effectiveness, toxic sid...

(This article belongs to the Special Issue Chitins 2015)
  • Article
  • Open Access
105 Citations
4,260 Views
6 Pages

1 October 2018

Immune checkpoint inhibitors (ICIS) such as inhibitors of CTLA-4, PD-1, and PD-L1, given as monotherapy or combination therapy have emerged as effective treatment options for immune-sensitive solid tumours and hematologic malignancies. The benefits o...

  • Article
  • Open Access
11 Citations
3,302 Views
12 Pages

Distribution of Platinum and Palladium between Dissolved, Nanoparticulate, and Microparticulate Fractions of Road Dust

  • Mikhail S. Ermolin,
  • Alexandr I. Ivaneev,
  • Anton S. Brzhezinskiy,
  • Natalia N. Fedyunina and ,
  • Vasily K. Karandashev and
  • Petr S. Fedotov
  • + 1 author+ 0 author

19 September 2022

Ageing processes of vehicle catalytic converters inevitably lead to the release of Pt and Pd into the environment, road dust being the main sink. Though Pt and Pd are contained in catalytic converters in nanoparticulate metallic form, under environme...

(This article belongs to the Special Issue Advances in Detection of Trace Elements by Analytical Spectroscopy)
  • Review
  • Open Access
60 Citations
6,466 Views
18 Pages

16 September 2020

Survival outcomes in extensive-stage small cell lung cancer (ES SCLC) are dismal, with median overall survival (OS) less than 12 months. The combination of PD-1/PD-L1 immune checkpoint inhibitors (ICIs) with first-line platinum-etoposide chemotherapy...

(This article belongs to the Section Systematic Review or Meta-Analysis in Cancer Research)
  • Article
  • Open Access
20 Citations
4,374 Views
20 Pages

Polydatin Inhibits Hepatocellular Carcinoma Cell Proliferation and Sensitizes Doxorubicin and Cisplatin through Targeting Cell Mitotic Machinery

  • Umar Farooq,
  • Hao Wang,
  • Jingru Hu,
  • Guangyue Li and ,
  • Shah Jehan,
  • Jinming Shi,
  • Dangdang Li and
  • Guangchao Sui
  • + 3 authors+ 0 author

4 January 2023

Polydatin (PD) is a natural compound with anticancer activities, but the underlying mechanisms remain largely unclear. To understand how PD inhibited hepatocellular carcinoma (HCC), we studied PD treatments in HCC HepG2 and SK-HEP1 cells, and normal...

(This article belongs to the Section Cell Proliferation and Division)
  • Review
  • Open Access
11 Citations
3,527 Views
11 Pages

Ocular Surface Features in Patients with Parkinson Disease on and off Treatment: A Narrative Review

  • Matilde Buzzi,
  • Giuseppe Giannaccare,
  • Michela Cennamo,
  • Federico Bernabei and ,
  • Pierre-Raphael Rothschild,
  • Aldo Vagge,
  • Vincenzo Scorcia and
  • Rita Mencucci
  • + 3 authors+ 0 author

19 December 2022

Parkinson disease (PD) is a progressive, neurodegenerative disease of the central nervous system. Visual disturbance is one of the most frequent nonmotor abnormalities referred to by patients suffering from PD at early stages. Furthermore, ocular sur...

(This article belongs to the Collection New Diagnostic and Therapeutic Developments in Eye Diseases)
  • Article
  • Open Access
38 Citations
10,090 Views
18 Pages

Toxic Oligomeric Alpha-Synuclein Variants Present in Human Parkinson’s Disease Brains Are Differentially Generated in Mammalian Cell Models

  • Wei Xin,
  • Sharareh Emadi,
  • Stephanie Williams,
  • Qiang Liu and ,
  • Philip Schulz,
  • Ping He,
  • Now Bahar Alam,
  • Jie Wu and
  • Michael R. Sierks
  • + 4 authors+ 0 author

22 July 2015

Misfolding and aggregation of α-synuclein into toxic soluble oligomeric α-synuclein aggregates has been strongly correlated with the pathogenesis of Parkinson’s disease (PD). Here, we show that two different morphologically distinct oligomeric α-synu...

(This article belongs to the Special Issue Exploring the Mechanisms by which α-Synuclein Kills Cells in Parkinson Disease)
  • Article
  • Open Access
47 Citations
5,556 Views
12 Pages

Robotic Stereotactic Radiosurgery in Melanoma Patients with Brain Metastases under Simultaneous Anti-PD-1 Treatment

  • Maike Trommer-Nestler,
  • Simone Marnitz,
  • Martin Kocher,
  • Daniel Rueß and ,
  • Max Schlaak,
  • Sebastian Theurich,
  • Michael Von Bergwelt-Baildon,
  • Janis Morgenthaler,
  • Karolina Jablonska and
  • Christian Baues
  • + 7 authors+ 2 authors

7 September 2018

Combination concepts of radiotherapy and immune checkpoint inhibition are currently of high interest. We examined imaging findings, acute toxicity, and local control in patients with melanoma brain metastases receiving programmed death 1 (PD-1) inhib...

(This article belongs to the Special Issue Partnership of Radiotherapy and Immunotherapy)
  • Article
  • Open Access
16 Citations
4,274 Views
15 Pages

Phloroglucinol Derivative Carbomer Hydrogel Accelerates MRSA-Infected Wounds’ Healing

  • Xiaosu Huang,
  • Junhua Yang,
  • Renyue Zhang,
  • Lianbao Ye and ,
  • Ming Li and
  • Weiqiang Chen
  • + 1 author+ 0 author

Globally, wound infection is considered to be one of the major healthcare problems, with bacterial infections being the most critical threat, leading to poor and delayed wound healing, and even death. As a superbug, methicillin-resistant Staphylococc...

(This article belongs to the Section Molecular Pharmacology)
  • Systematic Review
  • Open Access
3 Citations
4,621 Views
21 Pages

Anti-PD-1 Monoclonal Antibodies (mAbs) Are Superior to Anti-PD-L1 mAbs When Combined with Chemotherapy in First-Line Treatment for Metastatic Non-Small Cell Lung Cancer (mNSCLC): A Network Meta-Analysis

  • Joe Q. Wei,
  • Alexander Yuile,
  • Malinda Itchins,
  • Benjamin Y. Kong and ,
  • Bob T. Li,
  • Nick Pavlakis,
  • David L. Chan and
  • Stephen J. Clarke
  • + 3 authors+ 0 author

Platinum-based chemotherapy combined with anti-PD-1 or PD-L1 monoclonal antibodies (mAbs) is now standard first-line therapy for mNSCLC patients without sensitizing driver mutations. Anti-PD-1 and anti-PD-L1 mAbs are considered to be equivalent in ef...

(This article belongs to the Section Immunology and Immunotherapy)
  • Article
  • Open Access
48 Citations
5,218 Views
21 Pages

4 May 2021

The green chemistry method is the preferred approach for synthesizing metal and metal oxide nanoparticles because of its low toxicity, environmental friendliness, feasibility, and safety to human health compared with other chemical or physical method...

(This article belongs to the Special Issue Advanced Research on the Removal of Pollutants by Nanomaterials)
  • Perspective
  • Open Access
17 Citations
4,627 Views
9 Pages

The surge in antimicrobial resistance and the limited availability of new antimicrobial drugs has fueled the interest in optimizing antibiotic dosing. An ideal dosing regimen leads to maximal bacterial cell kill, whilst minimizing the risk of toxicit...

(This article belongs to the Special Issue Antimicrobial Therapy in Intensive Care Unit)
  • Review
  • Open Access
14 Citations
5,545 Views
33 Pages

Alternative Strategies for Delivering Immunotherapeutics Targeting the PD-1/PD-L1 Immune Checkpoint in Cancer

  • Ryunosuke Hoshi,
  • Kristyna A. Gorospe,
  • Hagar I. Labouta,
  • Taha Azad and ,
  • Warren L. Lee and
  • Kelsie L. Thu
  • + 1 author+ 0 author

The programmed death-1/programmed death-ligand 1 (PD-1/PD-L1) immune checkpoint constitutes an inhibitory pathway best known for its regulation of cluster of differentiation 8 (CD8)+ T cell-mediated immune responses. Engagement of PD-L1 with PD-1 exp...

(This article belongs to the Special Issue Drug Repurposing and Delivery Systems for Immunotherapy)
  • Article
  • Open Access
36 Citations
7,012 Views
13 Pages

Natural Alkaloid Compounds as Inhibitors for Alpha-Synuclein Seeded Fibril Formation and Toxicity

  • Simona S. Ghanem,
  • Hend S. Fayed,
  • Qi Zhu,
  • Jia-Hong Lu and ,
  • Nishant N. Vaikath,
  • Janarthanan Ponraj,
  • Said Mansour and
  • Omar M. A. El-Agnaf
  • + 3 authors+ 0 author

19 June 2021

The accumulation and aggregation of α-synuclein (α-syn) is the main pathologic event in Parkinson’s disease (PD), dementia with Lewy bodies, and multiple system atrophy. α-Syn-seeded fibril formation and its induced toxicity occupy a major role in PD...

(This article belongs to the Special Issue Natural Bioactive Compounds against Neurodegenerative Diseases: Mechanistic Approach)
  • Article
  • Open Access
1,088 Views
16 Pages

Impact of PD-L1 Status on the Development of Cutaneous Immune-Related Adverse Events in Non-Small-Cell Lung Cancer Patients Receiving Immunotherapy

  • Alexander Yakobson,
  • Fahed Abu Salamah,
  • Ibrahim Alatawneh,
  • Ahron Yehonatan Cohen and ,
  • Yuliya Valdman-Grinshpoun,
  • Yotam Malek,
  • Itamar Gothelf,
  • Ashraf Abu Jama,
  • Nashat Abu Yasin and
  • Walid Shalata
  • + 8 authors+ 3 authors

9 April 2026

Background: Cutaneous adverse events (cAEs) are among the most frequent immune-related toxicities associated with immune checkpoint inhibitors (ICIs). Previous clinical trials have reported higher rates of dermatologic toxicity with anti-CTLA-4 agent...

(This article belongs to the Section Medical Research)

of 19